Jiangsu Nhwa Pharmaceutical: Announcement on the Consistency Evaluation of Liraglutide Tablets as Generic Drugs.
Jiangsu Nhwa Pharmaceutical: Announcement on the acquisition of the Pharmaceutical Registration Certificate for Praline Capsules
Jiangsu Nhwa Pharmaceutical: Announcement on the Consistency Evaluation of Generic Salted Ephedrine Hydrochloride Injection
Jiangsu Nhwa Pharmaceutical: Announcement of the resolution of the 10th meeting of the 6th Supervisory Board.
Jiangsu Nhwa Pharmaceutical: Announcement of Resolutions of the 11th Meeting of the 6th Board of Directors
Jiangsu Nhwa Pharmaceutical: Assessment and management method for the implementation of restricted stock incentive plan in 2024.
Jiangsu Nhwa Pharmaceutical: Independent Financial Advisor Report on Jiangsu Nhwa Pharmaceutical Co., Ltd.'s 2024 Restricted Stock Incentive Plan (Draft) by Shanghai Rongzheng Enterprise Consulting Service (Group) Co., Ltd.
Jiangsu Nhwa Pharmaceutical: Announcement on obtaining the “Drug Registration Certificate”
Enhua Pharmaceutical: 002262 Enhua Pharmaceutical Investor Relations Management Information 20240425
Enhua Pharmaceutical: Announcement of Supervisory Board Resolutions
Enhua Pharmaceutical: Announcement of Board Resolutions
Enhua Pharmaceutical: 002262 Enhua Pharmaceutical Investor Relations Management Information 20240409
Enhua Pharmaceutical: Announcement on NH103 Obtaining the “Drug Clinical Trial Approval Notice”
Enhua Pharmaceutical: 2023 Annual Audit Report
Enhua Pharmaceutical: 2023 Independent Director Debriefing Report (Wang Guangji)
Enhua Pharmaceutical: 2023 Independent Director Debriefing Report (Li Yulan)
Enhua Pharmaceutical: Working System for Independent Directors (Revised Draft)
Enhua Pharmaceutical: Special explanation of the company's cumulative and current external guarantees by independent directors
Enhua Pharmaceutical: Announcement of Supervisory Board Resolutions
Enhua Pharmaceutical: Constitution of Jiangsu Enhua Pharmaceutical Co., Ltd. (March 28, 2024)
No Data